Konarski Wojciech, Poboży Tomasz, Hordowicz Martyna
Department of Orthopaedic Surgery, Ciechanów Hospital, Ciechanów.
Outpatient Pain Clinic, Hospice of St. Christopher in Warsaw.
Orthop Rev (Pavia). 2022 Apr 25;14(3):33875. doi: 10.52965/001c.33875. eCollection 2022.
Numerous strategies are used to decrease the risk of the need for [allogeneic blood transfusion (ABT)], including [tranexamic acid (TXA)].
In a single-center retrospective observational study, we have assessed the impact of TXA on the need and average volume of blood used during transfusion.
We have reviewed medical records of a total of 491 patients undergoing arthroplasty in our hospital from Dec 2016 to Dec 2019.
226 patients were administered TXA IV, and 265 did not receive an additional intervention. In the TXA group, 7/226 patients required ABT vs. 41/265 in the non-TXA group (p<0,001). The Non-TXA group required a significantly higher blood transfusion volume than the TXA group (mean 82,42 mL vs. 12,74 mL; p<0,001).
We conclude that two doses of 1g TXA administered [intravenously (IV)] before incision and during skin suturing reduce the need for blood transfusion in patients undergoing JRS.
为降低[异体输血(ABT)]需求风险,人们采用了多种策略,包括[氨甲环酸(TXA)]。
在一项单中心回顾性观察研究中,我们评估了氨甲环酸对输血期间用血需求和平均用量的影响。
我们回顾了2016年12月至2019年12月在我院接受关节置换术的491例患者的病历。
226例患者静脉注射氨甲环酸,265例未接受额外干预。氨甲环酸组中,7/226例患者需要异体输血,而非氨甲环酸组为41/265例(p<0.001)。非氨甲环酸组的输血需求量显著高于氨甲环酸组(平均82.42 mL对12.74 mL;p<0.001)。
我们得出结论,在切口前和皮肤缝合期间静脉注射两剂1g氨甲环酸可降低接受关节置换术患者的输血需求。